Join to access to all OVN content. Join for Free
Why Companies Should Hire Aspiring MSLs (and How)
MSL role Medical Science Liaison aspiring MSLs networking in medical affairs diversity hiring in pharmaceuticals

Why Companies Should Hire Aspiring MSLs (and How)


Share This Article


Summary

In this episode, Alyson Evans joins Tom Caravela to discuss the evolving landscape of the MSL role. Alyson shares her career journey and offers insights on hiring practices, comparing the strengths of aspiring versus experienced MSLs. She provides comprehensive advice for those looking to break into the field, highlighting the importance of networking and purposeful diversity in hiring. Alyson also predicts future trends that could shape the MSL role. The episode wraps up with final thoughts and actionable advice for aspiring MSLs, encouraging listeners to remain proactive and engaged in their career development.

My guest today is Alyson Evans, Director, Medical Affairs with Sirtex Pharmaceuticals. Alyson discusses why companies should consider hiring aspiring MSLs.

She shares…

๐Ÿ‘‰ Why she considers hiring aspiring MSLs and what her experience has been
๐Ÿ‘‰ The advantages and disadvantages of hiring aspiring MSLs
๐Ÿ‘‰ How to go about hiring aspiring MSLs
๐Ÿ‘‰ What “purposeful diversity hiring” is
๐Ÿ‘‰ What advice she has for aspiring MSLs looking to land a role as a Medical Science Liaison

Click for Source
MSL role, Medical Science Liaison, aspiring MSLs, networking in medical affairs, diversity hiring in pharmaceuticals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%โ€‹
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%โ€‹

Explore OVN